GlaxoSmithKline (GSK) has plans to open an approximately $549m (£400m) biotechnology campus in Stevenage, UK, which would possibly create up to 5,000 skilled jobs in the coming five to ten years.
GlaxoSmithKline (GSK) is set to leverage the Cell and Gene Therapy (CGT) Catapult’s facility in Stevenage to expand its own clinical trial manufacturing capacity for cell and gene therapy.